The combined use of the two antibodies on EGFR-mutated NSCLC increases the number of tumor-infiltrating CD8+ T cells and enhances the production of IFN-γ and tumor necrosis factor-α (TNF-α), which can prominently inhibit tumor growth[51], providing a theoretical foundation for the design of subsequent clinical trials. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.